Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018510 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1 study of Healthy and HIV, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT02018510: Completed Phase 1 study of Healthy and HIV, sponsored by Rockefeller University.
NCT02018510 is a Phase 1 study of Healthy and HIV that has completed, run by Rockefeller University. The registered enrollment target is 49 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02018510, a Phase 1 study of Healthy and HIV, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The proposed study is a first-in-man phase I study that aims to evaluate the safety, tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and its antiretroviral activity in HIV-infected subjects.
Primary Outcome
To evaluate the safety and tolerability profile of one or two intravenous infusions of 3BNC117 at 3 increasing dose levels in HIV-infected and HIV-uninfected individuals.
Interventions
- BIOLOGICAL 1 mg/kg, single dose IV administration of 3BNC117
- BIOLOGICAL 3 mg/kg, single dose IV administration of 3BNC117
- BIOLOGICAL 10 mg/kg, single dose IV administration of 3BNC117
- BIOLOGICAL 30 mg/kg, single dose IV administration of 3BNC117
- BIOLOGICAL 10 mg/kg, two doses IV of 3BNC117
Study Locations (4)
New York
- The Rockefeller University - New York
- Weill Cornell Medical Center - New York
Massachusetts
- Brigham and Women's Hospital - Boston
Other
- University of Cologne - Cologne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
What the finished NCT02018510 record still lists
NCT02018510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which 1 mg/kg, single dose IV administration of 3BNC117 is the first listed.
NCT02018510 reports a single indexed study location in New York, Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT02018510 about?
NCT02018510 is a clinical study titled "A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117". The proposed study is a first-in-man phase I study that aims to evaluate the safety, tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and its antiretroviral activity in HIV-infected subjects.
What is the current status of trial NCT02018510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2014-01. Estimated completion is 2016-01.
What conditions does trial NCT02018510 study?
This clinical trial studies the following conditions: Healthy, HIV.
What interventions are being tested in trial NCT02018510?
The interventions under investigation include: 1 mg/kg, single dose IV administration of 3BNC117 (BIOLOGICAL), 3 mg/kg, single dose IV administration of 3BNC117 (BIOLOGICAL), 10 mg/kg, single dose IV administration of 3BNC117 (BIOLOGICAL), 30 mg/kg, single dose IV administration of 3BNC117 (BIOLOGICAL), 10 mg/kg, two doses IV of 3BNC117 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02018510?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02018510 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02018510's enrollment target sits among peer trials
49 474th of 1090 higher than 613 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia